Bayer invests in hemophilia gene therapy head-start
This article was originally published in Scrip
Executive Summary
Bayer HealthCare has paid $20m upfront to Dimension Therapeutics as part of an early-stage collaboration to develop some of the first novel gene therapies to treat hemophilia A.